Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 361 to 362 of 362 entries
Sorted by: Best Match Show Resources per page
COVID-19 associated mucormycosis: evolving technologies for early and rapid diagnosis.

3 Biotech

Samson R, Dharne M.
PMID: 34900512
3 Biotech. 2022 Jan;12(1):6. doi: 10.1007/s13205-021-03080-4. Epub 2021 Dec 06.

The post-coronavirus disease (COVID-19) mucormycosis is a deadly addition to the pandemic spectrum. Although it's a rare, aggressive, and opportunistic disease, the associated morbidity and mortality are significant. The complex interplay of factors aggravating CAM is uncontrolled diabetes, irrational...

Cite
Samson R, Dharne M. COVID-19 associated mucormycosis: evolving technologies for early and rapid diagnosis. 3 Biotech. 2021;12(1):6doi: 10.1007/s13205-021-03080-4.
Samson, R., & Dharne, M. (2022). COVID-19 associated mucormycosis: evolving technologies for early and rapid diagnosis. 3 Biotech, 12(1), 6. https://doi.org/10.1007/s13205-021-03080-4
Samson, Rachel, and Dharne, Mahesh. "COVID-19 associated mucormycosis: evolving technologies for early and rapid diagnosis." 3 Biotech vol. 12,1 (2022): 6. doi: https://doi.org/10.1007/s13205-021-03080-4
Samson R, Dharne M. COVID-19 associated mucormycosis: evolving technologies for early and rapid diagnosis. 3 Biotech. 2022 Jan;12(1):6. doi: 10.1007/s13205-021-03080-4. Epub 2021 Dec 06. PMID: 34900512; PMCID: PMC8647065.
Copy Download .nbib Format: NLM
Patient-Reported Functional Outcomes in Patients With Chronic Myeloid Leukemia After Stopping Tyrosine Kinase Inhibitors.

Journal of the National Cancer Institute

Schoenbeck KL, Atallah E, Lin L, Weinfurt KP, Cortes J, Deininger MWN, Kota V, Larson RA, Mauro MJ, Oehler VG, Pinilla-Ibarz J, Radich JP, Schiffer CA, Shah NP, Silver RT, Thompson JE, Flynn KE.
PMID: 34491344
J Natl Cancer Inst. 2022 Jan 11;114(1):160-164. doi: 10.1093/jnci/djab184.

Treatment-free remission (TFR) is a goal for patients with chronic myeloid leukemia (CML). Functional outcomes after discontinuing tyrosine kinase inhibitor (TKI) treatment have not been described. Patient-Reported Outcomes Measurement Information System (PROMIS) measures of social, physical, cognitive, and sexual...

Cite
Schoenbeck KL, Atallah E, Lin L, et al. Patient-Reported Functional Outcomes in Patients With Chronic Myeloid Leukemia After Stopping Tyrosine Kinase Inhibitors. J Natl Cancer Inst. 2022;114(1):160-164doi: 10.1093/jnci/djab184.
Schoenbeck, K. L., Atallah, E., Lin, L., Weinfurt, K. P., Cortes, J., Deininger, M. W. N., Kota, V., Larson, R. A., Mauro, M. J., Oehler, V. G., Pinilla-Ibarz, J., Radich, J. P., Schiffer, C. A., Shah, N. P., Silver, R. T., Thompson, J. E., & Flynn, K. E. (2022). Patient-Reported Functional Outcomes in Patients With Chronic Myeloid Leukemia After Stopping Tyrosine Kinase Inhibitors. Journal of the National Cancer Institute, 114(1), 160-164. https://doi.org/10.1093/jnci/djab184
Schoenbeck, Kelly L, et al. "Patient-Reported Functional Outcomes in Patients With Chronic Myeloid Leukemia After Stopping Tyrosine Kinase Inhibitors." Journal of the National Cancer Institute vol. 114,1 (2022): 160-164. doi: https://doi.org/10.1093/jnci/djab184
Schoenbeck KL, Atallah E, Lin L, Weinfurt KP, Cortes J, Deininger MWN, Kota V, Larson RA, Mauro MJ, Oehler VG, Pinilla-Ibarz J, Radich JP, Schiffer CA, Shah NP, Silver RT, Thompson JE, Flynn KE. Patient-Reported Functional Outcomes in Patients With Chronic Myeloid Leukemia After Stopping Tyrosine Kinase Inhibitors. J Natl Cancer Inst. 2022 Jan 11;114(1):160-164. doi: 10.1093/jnci/djab184. PMID: 34491344; PMCID: PMC8755495.
Copy Download .nbib Format: NLM
Showing 361 to 362 of 362 entries